You are here: Industry Insights > Proteostasis Therapeutics

News List

Proteostasis Announces In Vitro Data for Potential COVID-19 Treatment Candidate americanpharmaceuticalreview
June 05, 2020
Proteostasis Therapeutics announced results from in vitro studies evaluating the use of PTI-129 as a treatment for COVID-19.
Proteostasis Therapeutics Initiates Global Cystic Fibrosis Phase 2 Study americanpharmaceuticalreview
July 26, 2019
Proteostasis Therapeutics announced that the first patient has been dosed in the Company's 28-day, Phase 2 study evaluating its proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations in F508del homozygous and heteroz
Proteostasis Therapeutics Receives Orphan Drug Designation in the EU for PTI-428 americanpharmaceuticalreview
June 06, 2019
Proteostasis Therapeutics announced that the European Commission (EC) has granted orphan drug designation (ODD) to PTI-428 for the treatment of cystic fibrosis.
Shares in Proteostasis Therapeutics plunge on disappointing results for cystic fibrosis triplet therapy firstwordpharma
March 26, 2019
Proteostasis Therapeutics' stock dropped as much as 63 percent Monday after the company reported disappointing results regarding the effect……
Proteostasis Therapeutics Announces Global License Agreement with Genentech americanpharmaceuticalreview
December 18, 2018
Proteostasis Therapeutics announced a worldwide, exclusive license agreement with Genentech, a member of the Roche Group...
Proteostasis Therapeutics receives FDA approval for Cystic Fibrosis drug biospectrumasia
March 19, 2018
The FDA Office of Orphan Products Development grants Orphan Drug Designation to novel drugs or biologics that are intended for the treatment of rare diseases or conditions affecting fewer than 200,000 patients in the United States.
Proteostasis Therapeutics Snags Breakthrough Designation biospace
March 14, 2018
Investors in Cambridge, Mass.-based Proteostasis Therapeutics are smiling this morning after FDA granted the company’s investigational cystic fibrosis add-on therapy the Breakthrough Therapy Designation.